GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » E10

Biomarin Pharmaceutical (FRA:BM8) E10 : €-0.96 (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.423. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.96 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 6.50% per year. During the past 5 years, the average E10 Growth Rate was 6.00% per year. During the past 10 years, the average E10 Growth Rate was -14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biomarin Pharmaceutical was 20.60% per year. The lowest was -63.90% per year. And the median was 6.00% per year.

As of today (2024-04-27), Biomarin Pharmaceutical's current stock price is €76.62. Biomarin Pharmaceutical's E10 for the quarter that ended in Mar. 2024 was €-0.96. Biomarin Pharmaceutical's Shiller PE Ratio of today is .


Biomarin Pharmaceutical E10 Historical Data

The historical data trend for Biomarin Pharmaceutical's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical E10 Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.43 -1.09 -1.28 -1.22 -1.01

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.17 -1.18 -1.12 -1.01 -0.96

Competitive Comparison of Biomarin Pharmaceutical's E10

For the Biotechnology subindustry, Biomarin Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Shiller PE Ratio falls into.



Biomarin Pharmaceutical E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.423/129.4194*129.4194
=0.423

Current CPI (Mar. 2024) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

per share eps CPI Adj_EPS
201406 -0.169 100.560 -0.218
201409 0.039 100.428 0.050
201412 -0.381 99.070 -0.498
201503 -0.397 99.621 -0.516
201506 -0.454 100.684 -0.584
201509 -0.535 100.392 -0.690
201512 0.358 99.792 0.464
201603 -0.458 100.470 -0.590
201606 -2.296 101.688 -2.922
201609 -0.196 101.861 -0.249
201612 -0.502 101.863 -0.638
201703 -0.084 102.862 -0.106
201706 -0.187 103.349 -0.234
201709 -0.059 104.136 -0.073
201712 -0.253 104.011 -0.315
201803 -0.211 105.290 -0.259
201806 -0.077 106.317 -0.094
201809 -5.999 106.507 -7.290
201812 -0.026 105.998 -0.032
201903 -0.283 107.251 -0.341
201906 -0.186 108.070 -0.223
201909 0.272 108.329 0.325
201912 0.072 108.420 0.086
202003 0.398 108.902 0.473
202006 -0.142 108.767 -0.169
202009 3.404 109.815 4.012
202012 0.099 109.897 0.117
202103 0.076 111.754 0.088
202106 0.058 114.631 0.065
202109 -0.170 115.734 -0.190
202112 -0.283 117.630 -0.311
202203 0.572 121.301 0.610
202206 0.142 125.017 0.147
202209 -0.040 125.227 -0.041
202212 -0.001 125.222 -0.001
202303 0.252 127.348 0.256
202306 0.268 128.729 0.269
202309 0.197 129.860 0.196
202312 0.101 129.419 0.101
202403 0.423 129.419 0.423

Add all the adjusted EPS together and divide 10 will get our e10.


Biomarin Pharmaceutical  (FRA:BM8) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biomarin Pharmaceutical E10 Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (FRA:BM8) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines